AFRICAN AMERICAN ANTIPLATELET STROKE PREVENTION STUDY

非裔美国人抗血小板中风预防研究

• 批准号: 6197568
• 负责人: PHILIP B GORELICK
• 金额: $ 373.08万
• 依托单位: RUSH UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-07-01 至 2005-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6197568
• 关键词: African American; aspirin; cardiovascular disorder prevention; clinical research; clinical trials; fibrinolytic agents; human middle age (35-64); human old age (65+); human subject; human therapy evaluation; longitudinal human study; myocardial infarction; platelet aggregation inhibitors; relapse /recurrence; stroke; young adult human (21-34)

This is an application for the continuation of the ongoing trial "African-American Antiplatelet Stroke Prevention Trial (AAASP). This is a multicenter, randomized double blind clinical trial comparing ticlopidine (500 mg/day) with aspirin (650 mg/day). The purpose is to test the efficacy of the two treatments in preventing recurrent stroke, vascular death and myocardial infarction. Patients are enrolled no more than 90 days after incident cerebral infarction and are followed for 2 years. The investigators have already recruited 1400 of the needed 1800 subjects. Dr. Gorelick and colleagues have demonstrated their ability to conduct a trial of this magnitude having overcome initial difficulties in recruitment, which require the expansion to sites outside the Chicago area. They have currently completed two-thirds of the projected enrollment and should be able to continue to administer this trial competently to its conclusion.

这是一份继续进行中的审判的申请 非洲裔美国人抗血小板中风预防试验（AAASP）。这是一 噻氯匹定（500例）多中心随机双盲临床试验 阿司匹林（650 mg/天）。其目的是测试 预防复发性中风、血管性死亡和心肌梗死的两种治疗方法 梗塞患者入组不超过90天后发生脑卒中 梗死，并随访2年。调查人员已经 招募了1800名受试者中的1400名。 Gorelick博士和同事已经证明了他们进行试验的能力 在克服了最初的征聘困难之后， 需要扩展到芝加哥地区以外的地点。目前， 完成了三分之二的计划招生，应该能够继续 能胜任地完成这场审判